Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Trinity Biotech PLC maintains a gross margin of 35.44%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -42.02%, while the net margin is -80.23%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively TRIB converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, TRIB competes directly with industry leaders such as ALUR and RBOT. With a market capitalization of $13.46M, it holds a significant position in the sector. When comparing efficiency, TRIB's gross margin of 35.44% stands against ALUR's 49.06% and RBOT's N/A. Such benchmarking helps identify whether Trinity Biotech PLC is trading at a premium or discount relative to its financial performance.
